Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Total 13F shares
-
2,420,717
-
Share change
-
-830,223
-
Total reported value
-
$9,354,000
-
Price per share
-
$3.85
-
Number of holders
-
11
-
Value change
-
-$3,409,943
-
Number of buys
-
4
-
Number of sells
-
10
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q4 2018
As of 31 Dec 2018,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,420,717 shares.
The largest 10 holders included
Artemis Investment Management LLP, FMR LLC, CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM, Vanguard Group Inc, BlackRock Inc., UBS Group AG, DEUTSCHE BANK AG\, MORGAN STANLEY, BANK OF MONTREAL /CAN/, and Tower Research Capital LLC (TRC).
This page lists
11
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.